RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Steroid use fails to boost pregnancy rates in infertility treatments

Mar 1, 2007 - 5:00:00 AM
The compiled studies included couples who were infertile due to a wide variety of problems in either the woman, man or both partners.

 
[RxPG] There is no clear benefit from a hormone commonly prescribed to enhance the effectiveness of infertility treatments, according to a new review of studies.

The steroid hormones called glucocorticoids have potent effects on the body’s inflammatory and immune responses, so many fertility specialists prescribe them in hopes of making the lining of the uterus more receptive to embryo implantation. But lead review author Carolien Boomsma says that routine practice should stop.

“This meta-analysis shows that empirical use of glucocorticoids is not supported by evidence from studies,” she said. “Moreover, we don’t know enough about the possible adverse effects of glucocorticoids in early pregnancy. Therefore, at present, glucocorticoids should not be prescribed in this way,” said Boomsma, a researcher at the University Medical Centre Utrecht in the Netherlands.

The review appears in the most recent issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The review compares success rates between would-be mothers who took glucocorticoids around the time of embryo implantation and those who did not. All of the women underwent one of two types of assisted reproductive technology. In vitro fertilization (IVF) involves removing mature eggs from a woman’s ovary, mixing them with sperm in the laboratory, and placing the embryos in the woman’s reproductive tract. Intracytoplasmic sperm injection (ICSI) is another in vitro fertilization practice where a single sperm is injected directly into a harvested egg.

The meta-analysis pooled data from 13 studies including 1,759 couples. Every study was a randomized controlled trial, which is considered the most reliable form of scientific evidence.

The review found no overall improvement in pregnancy rates when the assisted reproductive technologies were combined with glucocorticoid treatment. However, six of the studies — of 650 women undergoing IVF — revealed a slightly higher pregnancy rate among women who took the hormones. The review authors say the difference barely exceeds that which could be attributed to mere chance.

“At present, glucocorticoids should not be offered as a routine procedure in women undergoing ART (assisted reproductive technologies), except in the context of well-designed studies,” the reviewers conclude.

Glucocorticoids can bring on problems such as infections or premature births. Though the available studies reported no significant increases in these negative outcomes, they were “poorly and inconsistently reported,” the review said. Further research is needed to clarify both benefits and harms, Boomsma and colleagues said.

Only three of the studies in the review continued long enough to report actual birth rates rather than simply pregnancy rates. “Trials should be of sufficient duration to have live birth as their primary outcome,” the authors say.

Despite substantial improvements in IVF and ICSI techniques, only 20 percent to 30 percent of couples go home with a healthy baby after each treatment cycle. That tantalizing hint of benefit may nevertheless encourage some practitioners to continue routine use of glucocorticoids for their IVF patients, said Randall Hines, M.D., director of the division of reproductive endocrinology and infertility at the University of Mississippi Medical Center.

“When you have a therapy that doesn’t have significant risk and doesn’t impose significant burden on the patient in terms of cost or inconvenience, it’s hard for people to let go of it,” said Hines, who was not involved in the review and does not prescribe glucocorticoids routinely in his practice.

The compiled studies included couples who were infertile due to a wide variety of problems in either the woman, man or both partners.

Future research may reveal that glucocorticoids do help specific subsets of these patients, the authors say. For example, women with unexplained infertility, endometriosis, recurrent implantation failure or certain immunological issues may benefit from the hormonal effects on uterine receptivity. None of the studies included in the review focused specifically on these patient groups.




Advertise in this space for $10 per month. Contact us today.


Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)